Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.
about
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspectivePlasticity of the Leishmania genome leading to gene copy number variations and drug resistanceLinking in vitro and in vivo survival of clinical Leishmania donovani strainsA novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cellsAntimonial resistance in Leishmania donovani is associated with increased in vivo parasite burdenTherapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c miceMolecular mechanisms of drug resistance in natural Leishmania populations vary with genetic backgroundTreatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, IndiaImipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infectionEx vivo host and parasite response to antileishmanial drugs and immunomodulatorsCurative effect of 18β-glycyrrhetinic acid in experimental visceral leishmaniasis depends on phosphatase-dependent modulation of cellular MAP kinases.Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stressCharacterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.The curative effect of fucoidan on visceral leishmaniasis is mediated by activation of MAP kinases through specific protein kinase C isoformsNitric oxide and redox mechanisms in the immune response.Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquinePost Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.Use of antimony in the treatment of leishmaniasis: current status and future directions.Antileishmanial effect of 18β-glycyrrhetinic acid is mediated by Toll-like receptor-dependent canonical and noncanonical p38 activationLeishmania donovani-induced ceramide as the key mediator of Akt dephosphorylation in murine macrophages: role of protein kinase Czeta and phosphatase.Upregulation of Cysteine Synthase and Cystathionine β-Synthase Contributes to Leishmania braziliensis Survival under Oxidative Stress.The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis.Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimonyTranscriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype.Inhibition of ABC transporters abolishes antimony resistance in Leishmania InfectionAntimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.In vivo/In vitro immune responses to L. major isolates from patients with no clinical response to Glucantime.Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony.Antimony resistance and environment: Elusive links to explore during Leishmania life cycle.Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.Liposomal cholesterol delivery activates the macrophage innate immune arm to facilitate intracellular Leishmania donovani killing.Leishmania antimony resistance: what we know what we can learn from the field.Immunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents.Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.Neurological disease in human and canine leishmaniasis--clinical features and immunopathogenesis.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Canine leishmaniasis in Southern Italy: a role for nitric oxide released from activated macrophages in asymptomatic infection?
P2860
Q28073426-78E86919-FF37-412E-AEA0-33D8F65DBDA8Q28074697-BA87234E-17B1-423D-B26B-05F9B4A5D57CQ28475170-BDBA59C7-6588-4DB6-AB21-D85816EEBCD5Q28476155-30785894-5CC8-422A-A766-924107271C2DQ28476400-0B9CAFCC-44DF-4AB7-8409-CEEC497983F2Q28477398-98D2B5B2-D27B-4B31-A015-CB132802034FQ28481297-A0B326FA-CABC-4672-B44E-8F250D72DBE5Q28484459-584C5079-3AD5-4439-BA7A-C0C6375ABF94Q28484622-C06AFFC5-F520-4323-B604-15E10CEB5B11Q28547648-9CB315A3-48B4-4A5B-95CB-3621159146E3Q31043850-1CB1B2C0-4EA2-45C9-B928-182B6110E5CBQ33587372-61B52E04-EF80-4AE1-854B-015D06B6CB3DQ33633393-97A53428-8C49-4FD1-BA6A-290B24E81349Q33797614-5AF3292D-47A5-42AE-B957-44B7B7D412C0Q33797823-675106CB-D3D2-4574-AF1E-CF08CFDBF84FQ33858274-4B13CAAC-74BD-499C-9700-687CCFD644C5Q35001939-AC261B5E-2BB4-444D-B003-7FD3CEC8F9ABQ35005213-7469EEAF-FC28-4B08-B53F-0F443E40DBD0Q35083527-B23F61CA-DD20-4DEE-B263-0F6E0345CC23Q35377767-C68B5704-3F09-48BD-9C37-6349E2CB8AA4Q35385952-E28267F4-B97D-45DC-92B5-59420037501CQ35784155-6B5A549B-41F7-4BEA-A6CC-C424878D6285Q35860144-64573D6D-BB6A-4C7B-8172-8CE450CDD32BQ35913098-2BB432CC-3348-4788-9564-0C8C7196ADDFQ36133198-3452BC2C-5807-4B0B-AF94-1C8DDB87E868Q36265092-3D107651-45DE-43B9-BF56-9A979D623723Q36482756-555100EE-3EBA-46CE-B5AB-3CA02A53EF3BQ36616938-D0367D4B-D3E6-4898-AAA7-7B5BC98D2554Q37157818-842F152B-CBA8-470E-A0ED-7500C4101A2FQ37390612-32D541A4-3494-4C5A-A8A6-E38863D9EC2EQ37390629-E0F6D36B-4E8B-4661-8726-2E4012DBE6B3Q37544427-F9B3DD76-9F43-4467-B836-C77864A263A6Q37546471-0C671B1E-1746-432B-ABC7-459033352B9AQ37907925-A90EF871-1BD1-4182-BAC8-3DFF31B950E2Q37991390-82CD3047-4E37-4564-B871-320100A0C5F9Q38040818-69ADEEE1-7F08-4AF1-9796-505305DA1A86Q38118386-B1597831-A7EA-435D-9ADD-934DD5821C1CQ38486593-A9D7BA2F-74B2-4627-B4D5-447A4D3FB65EQ38653256-F9D0E2D8-78C6-4594-BD8C-0FED6E81C3B8Q38737433-618F096A-E1A7-4E76-869C-585E3EAC7A5E
P2860
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@ast
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@en
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@nl
type
label
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@ast
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@en
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@nl
prefLabel
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@ast
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@en
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@nl
P2093
P2860
P1476
Sodium antimony gluconate indu ...... donovani-infected macrophages.
@en
P2093
Ananda Mookerjee
Bhaskar Saha
Jayati Mookerjee Basu
Ksudiram Naskar
Pradip Sen
Prosenjit Sen
Sanghamitra Raha
Soumitra K Choudhuri
Subha Banerjee
Suniti Bhaumik
P2860
P304
P356
10.1128/AAC.50.5.1788-1797.2006
P407
P577
2006-05-01T00:00:00Z